Merrimack Pharmaceuticals, Inc. (MACK)
  • CONTENT
Merrimack Pharmaceuticals, Inc. (MACK)
Merrimack Pharmaceuticals, Inc. (MACK)
Merrimack Pharmaceuticals, Inc. (MACK)
Merrimack Pharmaceuticals reports FY results
Merrimack Pharmaceuticals (NASDAQ: MACK ): FY GAAP EPS of -$4.55. More news on: Merrimack Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more …
Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results
CAMBRIDGE, Mass. , March 6, 2019 /PRNewswire/ --Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter and full year 2018 financial results for the period ended December 31, 2018 . …
Merrimack Pharmaceuticals, Inc. (MACK)